7.11 - R. Melcangi, Università di Milano

Condividi su
Data dell'evento: 07/11/2014
milano_torino_2

Venerdì 7 novembre - ore 12:00
Aula seminari, NICO 

An Update on Neuroactive Steroids
Roberto Cosimo Melcangi
Neuroendocrinology Unit - Department of Pharmacological and Biomolecular Sciences-Section of Biomedicine and Endocrinology; Center of Excellence on Neurodegenerative Diseases - University of Milan

melcangi

Neuroactive steroid family includes steroid hormones produced in peripheral glands and steroids directly synthesized in the nervous system (i.e., neurosteroids).These molecules, by mechanisms involving classical and/or non classical steroid receptors, act as important physiological regulators of nervous function, affecting mood, behavior, reproduction and cognition, as well as acting like protective agents in models of injury, neurodegenerative diseases and psychiatric disorders.

As reported, neuroactive steroid levels in central and peripheral nervous system are sex dimorphic and are influenced by hormonal environment. Moreover, data obtained in experimental models of Alzheimer's disease, Parkinson's disease, multiple sclerosis, peripheral neuropathy, psychiatric disorders etc. have shown that pathological conditions also alter the levels of neuroactive steroids and in some cases these changes occur in a sex-dimorphic way. Altogether, these observations may represent a background for possible neuroprotective strategies based on neuroactive steroids to be to be applied in human diseases.

Host: Alessandro Vercelli

download pdf

Agenda

16 febbraio 2019

Torino - 10th International Meeting STEROIDS and NERVOUS SYSTEM

Since 2001, this meeting represented an important event for basic and clinical researchers working on this emerging scientific topic. We will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, the vitamin D, neurodegenerative and psychiatric disorders, and the interference among endocrine disruptors and steroid signaling.

Ricerca

Identificato un nuovo bersaglio per contrastare la SMA

L’inibizione della proteina JNK rallenta la progressione della malattia che colpisce i motoneuroni ed è la prima causa genetica di morte nell’infanzia. Lo dimostra uno studio pubblicato su Frontiers in Molecular Neuroscience dal nostro gruppo di ricerca guidato da Alessandro Vercelli, in collaborazione con l’Istituto Mario Negri di Milano. Chiarire i meccanismi molecolari alla base della SMA può aprire la strada allo sviluppo di nuove terapie.

24 ottobre 2018